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ABSTRACT 1 
Fibroblast growth factor 23 (FGF23) regulates phosphate homeostasis and is linked 2 
to cardiovascular disease and all-cause mortality in chronic kidney disease. FGF23 3 
rises in patients with CKD stages 2-3 whereas in patients with autosomal dominant 4 
polycystic kidney disease (ADPKD), the increase of FGF23 precedes the first meas-5 
urable decline in renal function. The mechanisms governing FGF23 production and 6 
effects in kidney disease are largely unknown. We examined the correlation between 7 
FGF23 and its effects on mineral homeostasis in two PKD animal models. Plasma 8 
FGF23 levels were 10-fold increased in 4 weeks old cy/+ Han:SPRD rats, whereas 9 
plasma urea and creatinine concentrations were similar to controls. Plasma calcium 10 
and phosphate levels as well as TmP/GFR were similar in PKD and control rats at all 11 
time points. Expression and activity of renal phosphate transporters, the vitamin D3 12 
metabolizing enzymes, and the FGF23 co-ligand Klotho in the kidney were similar in 13 
PKD and control rats at 2, 4 and 8 weeks, indicating resistance to FGF23. However, 14 
phosphorylation of the FRS2a protein was enhanced. In PKD kidneys FGF23 mRNA 15 
was highly expressed and FGF23 protein was detected in cells lining renal cysts. 16 
FGF23 expression in bone and spleen was similar in PKD and healthy animals. Simi-17 
larly, in an inducible Pkd1 knockout mouse model plasma FGF23 levels were ele-18 
vated, FGF23 was expressed in kidneys whereas renal phosphate excretion was 19 
normal. Thus, the polycystic kidney produces FGF23 but is resistant to it. 20 
  21 
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INTRODUCTION 1 
Systemic phosphate homeostasis is regulated by a variety of factors including 2 
dietary intake, intestinal absorption, skeletal turnover, renal excretion, and systemic 3 
acid-base status as well as by many hormones. Among them parathyroid hormone 4 
(PTH), vitamin D3, and fibroblast growth factor 23 (FGF23) act in concert at various 5 
levels of systemic phosphate homeostasis.[1-10] 6 
FGF23 is a recently discovered member of the fibroblast growth factor family 7 
and is mainly expressed in bone and to a lesser extent in spleen, and brain but not in 8 
kidney.[11, 12] The kidney is the major target regulating phosphate reabsorption as well 9 
as vitamin D3 metabolism.[13, 14] FGF23 acts on the distal convoluted tubule which 10 
may lead to the triggering of a cascade that reduces proximal tubular phosphate re-11 
absorption.[15, 16] Alternatively in the proximal tubule FGF23 activates ERK1/2 and 12 
SGK1 phosphorylation (SGK1).[17] Phospho-SGK1 enables the phosphorylation of 13 
the sodium hydrogen exchanger regulatory factor (NHERF1) thereby allowing the 14 
internalization of the sodium phosphate cotransporter NaPi-IIa from the brush border 15 
membrane.[17] Consequently the reabsorption of phosphate from the glomerular fil-16 
trate will decrease.[15-17] Furthermore, FGF23 reduces the plasma concentration of 17 
1,25(OH)2 vitamin D3 through downregulation of Cyp27b1 (1α-hydroxylase) in the 18 
proximal tubule, the responsible enzyme for the 1α-hydroxylation of 25(OH) vitamin 19 
D3, and the upregulation of Cyp24a1 (24-OHase), the responsible enzyme for the 20 
degradation of active 1,25(OH)2 vitamin D3.[13, 14] 21 
The severe disturbance of phosphate homeostasis accounts for morbidity and 22 
mortality in patients with end-stage renal disease.[18] FGF23 is elevated in patients 23 
with CKD stages 2 and 3 whereas PTH increases significantly later.[19-22] In haemodi-24 
alysis patients FGF23 contributes to the excessive morbidity and mortality independ-25 
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ently of serum phosphate and PTH levels.[18] Moreover, CKD patients suffer from low 1 
vitamin D3 which may be caused at least in part by high FGF23 levels.[20, 22, 23] Simi-2 
larly, rats with progressive kidney disease showed elevated FGF23 levels.[24] In these 3 
animals, a neutralizing FGF23 antibody led to hyperphosphatemia and normalized 4 
1,25(OH)2 vitamin D3 levels.[24] 5 
ADPKD is a slowly progressive disease that is manifested by the replacement 6 
of functional renal tissue with growing cysts.[25] The responsible mutations lie in the 7 
PKD1 and PKD2 genes, encoding the two transmembrane proteins polycystin-1 8 
(PC1) and polycystin-2 (PC2), respectively.[26-30] ADPKD patients have 4-fold in-9 
creased FGF23 levels even before renal function declines.[31] Among these patients, 10 
only those with normal soluble α-Klotho, showed a mild decrease in plasma phos-11 
phate values.[31, 32] 12 
The Han:SPRD rat is a well-established PKD animal model with a mutation in 13 
the Pkdr1 gene that encodes the SamCystein protein.[33, 34] The slow progression of 14 
cystic kidney disease with a significant increase of creatinine and urea serum con-15 
centrations after 8 weeks is typical for heterozygous male animals (cy/+).[35] Cysts in 16 
the cy/+ animals originate mainly from the proximal tubule similar to mice with a dele-17 
tion in the Pkd1 gene.[35, 36] The PKD model has been widely used for examining 18 
mechanisms and therapies for ADPKD.[37-40] 19 
We investigated the regulation of renal phosphate handling, FGF23 expres-20 
sion, and production in two PKD animal models. We found that the polycystic kidney 21 
produces FGF23 but is resistant to it. 22 
  23 
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RESULTS 1 
Plasma concentrations of FGF23 and PTH 2 
FGF23 plasma concentrations were increased in cy/+ Han:SPRD rats com-3 
pared with wild type (+/+) animals at all time points studied (Figure 1a). At week 2, 4 
the difference in FGF23 concentration between cy/+ (55 ± 27 pg/ml) and +/+ animals 5 
(35 ± 11 pg/ml) was 20 pg/ml (95 % CI 0.5 – 39pg/ml). FGF23 plasma levels further 6 
increased in cy/+ animals to 549 pg/ml after 4 weeks (mean difference 497 pg/ml, 7 
95 % CI 444 – 549 pg/ml). FGF23 concentration in cy/+ animals remained approxi-8 
mately 10-fold higher at 6 and 8 weeks compared with controls. PTH plasma concen-9 
trations were similar in cy/+ and +/+ animals at 2 weeks (Figure 1b) whereas after 4 10 
weeks, PTH levels of cy/+ animals were 2-fold elevated (141 ± 16 pg/ml) compared 11 
with +/+ animals (63 ± 6 pg/ml) (mean difference 78 pg/ml, 95 % CI 64 - 92pg/ml). 12 
PTH concentration in cy/+ animals remained 2-fold higher at 6 and 8 weeks. 13 
The renal function parameters plasma creatinine and urea were similar for 14 
cy/+ and +/+ animals from birth to week 4, thereafter the values were higher in cy/+ 15 
compared with +/+ animals (Figures 1c and 1d). The estimated change of plasma 16 
creatinine per week in cy/+ animals was 2 µmol/l (95 % CI 1 - 3 µmol/l) and 0.8 µmol/l 17 
(95 % CI 0.7 – 1 µmol/l) in +/+ animals. For urea, the estimated change per week 18 
was 0.6 mmol/l (95 % CI 0.4 – 0.9 mmol/l) in cy/+ animals and 0.1 mmol/l (95 % CI 19 
0.1 – 0.2 mmol/l) in +/+ animals. At week 4, we measured plasma phosphate and 20 
calcium as well as TmP/GFR and creatinine clearance of cy/+ and control Han:SPRD 21 
rats after an overnight fast (Supplementary Figure 1). All parameters were similar in 22 
both groups. 23 
 24 
 25 
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FGF23 expression in cystic kidneys 1 
In order to identify the source(s) of elevated FGF23 in cy/+ Han:SPRD rats, we 2 
extracted mRNA from bone, kidney, spleen, heart, and liver and assessed FGF23 3 
mRNA expression by semi-quantitative real-time PCR. In bone, FGF23 expression 4 
increased over time in cy/+ and healthy animals but there were no differences be-5 
tween the groups at all time points studied (Figure 2a). In addition, we detected sta-6 
ble FGF23 mRNA expression in spleen whereas no FGF23 mRNA expression was 7 
found in liver and heart tissue in both animal groups (results not shown). In polycystic 8 
kidneys increasing levels of FGF23 mRNA were detectable after 4 weeks. However, 9 
in healthy kidneys no FGF23 mRNA expression was detected (Figure 2a). FGF23 10 
protein expression was detected by immunohistochemistry in cells lining the cysts in 11 
kidneys from cy/+ Han:SPRD rats but not in control kidneys (Figure 2b-f). Dmp1 and 12 
Fam20c modulate FGF23 expression in bone. We detected mRNA of both molecules 13 
in rat kidney at high levels. Fam20c expression was similar in cy/+ and control rats 14 
but Dmp1 expression was increased in kidneys from 8 weeks old cy/+ rats (Supple-15 
mentary Figure 2).  16 
 17 
1,25(OH)2 vitamin D3 metabolism 18 
Plasma 1,25(OH)2 vitamin D3 levels were similar among cy/+ and control ani-19 
mals at 2, 4, and 8 weeks (Figure 3a). In both groups 1,25(OH)2 vitamin D3 levels 20 
decreased similarly over time. The relative mRNA expression of vitamin D receptor 21 
(VDR) is similar in both groups whereas there is a reduction of VDR from week 4 to 8 22 
in cy/+ animals (Figure 3b). In addition, the relative mRNA expression of Cyp27b1 23 
and Cyp24a1, the major enzymes responsible for vitamin D3 metabolism was meas-24 
ured (Figures 3c and 3d). The mRNA expression of the catabolic enzyme Cyp24a1 25 
was higher at 2 weeks in cy/+ animals. However, the expression of Cyp24a1 was 26 
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similar in cy/+ and +/+ animals after 4 and 8 weeks. For the anabolic enzyme 1 
Cyp27b1, we detected similar mRNA expression levels in the cy/+ and +/+ groups at 2 
all time points studied. 3 
Renal phosphate and calcium handling 4 
To evaluate the biological effect of high FGF23 plasma levels, we measured 5 
phosphate and calcium concentrations in blood and urine. The plasma phosphate 6 
and calcium levels as well as the renal excretion of calcium and phosphate were 7 
similar among cy/+ and +/+ animals at all time points studied (Figure 4). 8 
Phosphate cotransporters NaPi-IIa and NaPi-IIc 9 
The renal phosphate cotransporters NaPi-IIa and NaPi-IIc are downregulated 10 
by high levels of FGF23. In our study, the mRNA and protein expression levels of 11 
NaPi-IIa and NaPi-IIc were similar in both groups at 2, 4, and 8 weeks (Figures 5 and 12 
6). Immunolocalization of NaPi-IIa protein in kidney sections of 4 and 8 weeks old 13 
cy/+ and +/+ animals demonstrated expression of NaPi-IIa protein in the brush border 14 
membrane of proximal tubules and smaller cysts as evident from colocalization with 15 
actin (Supplementary Figure 3). At these time points, basolateral NaPi-IIa staining 16 
was absent, whereas a prior report demonstrated aberrant NaPi-IIa localization in 32 17 
weeks old Han:SPRD rats.[41] 18 
Phosphate and glucose transport activities 19 
We tested the sodium-dependent transport rate of 32-labeled phosphate into 20 
brush border membrane vesicles in the absence and presence of phosphonoformic 21 
acid (PFA, 6 mM), an inhibitor of NaPi-IIa and NaPi-IIc, and found similar transport 22 
rates among cy/+ and control animals at 2 and 4 weeks (Figure 7). Na+-dependent 23 
phosphate uptake in the absence of PFA was significantly increased in kidneys of 8 24 
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weeks old cy/+ rats. 3H-glucose uptake was similar in both groups at all time points 1 
studied. 2 
FGF23 and left ventricular hypertrophy (LVH) 3 
High FGF23 plasma levels are associated with LVH.[42] We analyzed whether high 4 
FGF23 levels in 4 and 8 weeks old rats were associated with LVH but no difference 5 
was found for heart wall or septum thickness, heart to body weight or heart weight to 6 
tibia length (Supplementary Figure 4). 7 
Klotho expression and FRS2a phosphorylation state 8 
Since cy/+ animals appear to be resistant to the expected normal biological actions of 9 
FGF23 we examined whether Klotho availability or FGF23 signaling via the FGFR-1 10 
receptor may be altered. We observed similar relative Klotho mRNA expression in 11 
cy/+ and +/+ animals at 2 and 4 weeks whereas at 8 weeks, Klotho mRNA expres-12 
sion was reduced in cy/+ animals (Figure 8a). Klotho protein abundance was similar 13 
in 8 weeks old cy/+ and +/+ animals (Figure 8b). Relative mRNA expression levels of 14 
FGFR-1 in kidney and bone were similar among cy/+ and +/+ animals (Supplemen-15 
tary Figure 5). The downstream signaling of FGF23, Klotho, and FGFR-1 complex 16 
leads to the phosphorylation of the FGF receptor substrate 2 alpha (FRS2a). Total 17 
FRS2a was similar in kidneys from 8 week old cy/+ and +/+ rats, whereas phosphory-18 
lated FRS2a protein was increased (Figure 8c). 19 
Elevated plasma FGF23 and renal expression of FGF23 in conditional Pkd1 KO 20 
mice 21 
We employed a second model of PKD, the conditional Pkd1 KO mice where deletion 22 
of Pkd1 gene can be induced. We induced Pkd1 deletion at days 15-19 after birth 23 
which result in a slow progression of cystic kidney disease.[43] Pkd1 mRNA was 24 
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strongly reduced in kidneys and bone from 10 week old Pkd1fl/fl, cre+ mice as com-1 
pared to Pkd1fl/fl, cre- mice (Supplementary Figure 6). Conditional Pkd1 KO elevated 2 
intact FGF23 plasma levels in 10 weeks old Pkd1fl/fl, cre+ (277 ± 130 pg/ml) com-3 
pared to Pkd1fl/fl, cre- mice (199 ± 57 pg/ml) whereas TmP/GFR and creatinine clear-4 
ance was similar in knockout and healthy animals (Figure 9). Intact PTH did not differ 5 
between Pkd1fl/fl, cre+ (176 ± 71 pg/ml) and Pkd1fl/fl, cre- (253±126 pg/ml) mice (Fig-6 
ure 9). Similar to the rat model, Pkd1fl/fl, cre+ mice expressed similar FGF23 mRNA 7 
levels in bone as the control mice. Kidneys from Pkd1fl/fl, cre+ mice expressed FGF23 8 
mRNA and protein but not kidneys from Pkd1fl/fl, cre- (Figure 10 and Supplementary 9 
Figure 7). 10 
  11 
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DISCUSSION 1 
Our study provides four major findings: i) the Han:SPRD rat model accurately 2 
reproduces the observed increase of FGF23 levels in the early disease course of 3 
human ADPKD with normal kidney function, ii) Han:SPRD rats show resistance to 4 
highly elevated FGF23 levels as evident from normal phosphatemia, unchanged re-5 
nal phosphate excretion, preserved expression of renal phosphate cotransporters, 6 
increased PTH, normal 1,25(OH)2 vitamin D3 levels, and normal expression of 7 
Cyp27b1, iii) expression of FGF23 in polycystic kidneys, and iv) reproduction of the 8 
major findings in a second model of ADPKD, the inducible Pkd1 KO mouse. 9 
ADPKD patients with an estimated GFR of 60 ml/min/1.73m2 and higher dis-10 
play strongly elevated FGF23 levels but only a small fraction of these patients pre-11 
sent a reduction in renal phosphate reabsorption – albeit small – and a very mild hy-12 
pophosphatemia.[31] In ADPKD patients with normal renal phosphate handling de-13 
spite high FGF23 levels, reduced soluble Klotho levels were found whereas ADPKD 14 
patients that appeared to retain sensitivity to high FGF23 levels had preserved solu-15 
ble Klotho levels.[32] However, the temporal sequence of rising FGF23 in PKD, the 16 
mechanisms underlying resistance to the biological actions of FGF23, and the source 17 
and cause of the elevated FGF23 levels remained unclear. 18 
Herein, we demonstrate that intact FGF23 concentration in the cy/+ 19 
Han:SPRD rats increases early after birth before renal function decreases. The high 20 
FGF23 levels were accompanied by a 2-fold increase in PTH and normal 1,25(OH)2 21 
vitamin D3 levels. Plasma creatinine and urea indicated a decrease in renal function 22 
in cy/+ animals 6 weeks after birth and thereby 4 weeks after the rise in FGF23 and 23 
PTH.[35] Similarly, the inducible Pkd1 KO mouse, a second ADPKD model, has ele-24 
vated plasma FGF23 levels whereas creatinine clearance, TmP/GFR, and intact PTH 25 
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were normal. Thus, Han:SPRD rats and Pkd1 KO mice illustrate an increase in 1 
FGF23 levels similar to that observed in young ADPKD patients with preserved renal 2 
function, thus allowing to approach the underlying mechanisms in more detail. 3 
In healthy subjects and animals, a rise in FGF23 results in increased urinary 4 
excretion of phosphate through reduced expression of renal phosphate 5 
cotransporters, thus leading to a lowering of systemic serum phosphate concentra-6 
tions; concomitant reduction in circulating levels of active 1,25(OH)2 vitamin D3 levels 7 
occurs [44] which may participate in serum phosphate reduction. 8 
ADPKD patients and the PKD rodent models are resistant to the elevated 9 
FGF23 as indicated by normophosphatemia, normal renal phosphate excretion, un-10 
changed expression and activity of renal phosphate cotransporters, and apparently 11 
normal vitamin D3 metabolism. Moreover, the expression and activity of the main re-12 
nal phosphate cotransporters NaPi-IIa and NaPi-IIc are unchanged or elevated as 13 
indicated by immunoblotting, transport studies, and immunolocalization whereas in 14 
mice, overexpressing FGF23, NaPi-IIa mRNA and protein expressions are down reg-15 
ulated.[45] No left ventricular hypertrophy was detected suggesting either that FGF23 16 
requires longer time periods, stronger elevation or that the heart is also resistant to 17 
high FGF23 levels. 18 
Vitamin D3 metabolism is similar in polycystic and control rats: indeed plasma 19 
1,25(OH)2 vitamin D3 concentrations and mRNA expression of Cyp27b1 did not differ 20 
between both groups of animals. Cyp24a1 was upregulated at 2 weeks in PKD ani-21 
mals which could be due to an early rise of plasma FGF23 concentration, but this 22 
effect was only transient and not observed at later time points. 23 
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We further investigated underlying mechanisms of resistance and found nor-1 
mal expression of the FGFR-1 receptor mediating the biological effects of FGF23 in 2 
the kidney.[14, 46] Mice constitutively expressing FGF23 have no changes in FGFR-1 3 
expression levels suggesting that FGF23 per se does not modulate FGFR-1 expres-4 
sion.[45] Klotho is required to elicit FGF23 signals via the FGFR1 receptor.[14] In our 5 
PKD model Klotho protein abundance was unchanged. The activation of the 6 
Klotho/FGFR-1 complex leads to the phosphorylation of FRS2a. In the HanSPRD 7 
model pFRS2a was increased in cy/+ kidneys suggesting that FGF23 signaling can 8 
be induced but may be blocked further downstream.  9 
PKD animals have also higher PTH levels than control animals which are in 10 
contrast to ADPDK patients with normal eGFR.[31] The elevation of PTH levels was 11 
also observed in other CKD rat models and may be due to the faster disease pro-12 
gression in animals compared with humans.[22, 24] Measurement of plasma PTH at 13 
shorter intervals or studies in another animal model with slower disease progression 14 
might overcome this gap. FGF23 suppresses PTH secretion in healthy rats but loss 15 
of Klotho expression in parathyroid glands may be involved in the induction of FGF23 16 
resistance and secondary hyperparathyroidism.[47, 48] 17 
We further analyzed the source(s) of elevated FGF23 by examining FGF23 mRNA 18 
expression in different organs such as bone as the major source of FGF23 in health, 19 
spleen, kidney, heart, and liver. In wildtype animals, we detected FGF23 mRNA ex-20 
pression mainly in bone, and very small amounts were also observed in spleen, 21 
whereas PKD rats and mice expressed FGF23 mRNA and protein also in the poly-22 
cystic kidneys more precisely in the cells lining the cysts. In the rat and mouse PKD 23 
animal models FGF23 mRNA expression levels increased only in the polycystic kid-24 
neys whereas bone expressed similar mRNA levels in both groups suggesting that 25 
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kidney may be the major source of elevation of FGF23 levels in PKD. Similarly, in 1 
diabetic nephropathy the kidney may become a source of FGF23.[49] The mecha-2 
nisms causing ectopic FGF23 expression in kidney are currently unknown. Interest-3 
ingly, the kidney expresses several regulators of FGF23 secretion in bone such as 4 
Dmp1 and Fam20c and we found upregulation of Dmp1 in polycystic kidneys. In dia-5 
betic nephropathy, renal FGF23 expression was suppressed by ACE inhibition.[49] 6 
Several rodent models have been reported with elevated FGF23 levels induced by 7 
deletion of the OSR1 and SPAK protein kinases expressed in kidney.[50, 51] Whether 8 
these kinases contribute to elevated FGF23 levels in ADPKD models remains to be 9 
elucidated. 10 
In summary, we found 10-fold elevated FGF23 levels in PKD animals and re-11 
sistance of the target organs to its biological actions at early stage of polycystic kid-12 
ney disease. The polycystic kidney may be a major source of FGF23 in this type of 13 
nephropathy. 14 
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METHODS 1 
Animals 2 
The Han:SPRD rat colony was established in our animal facility from a litter which 3 
was obtained from the Rat Resource and Research Center (Columbia, MO) [40]. Male 4 
heterozygous cystic (cy/+) and wild-type (+/+) rats were used in this study. Pkd1 5 
floxed/floxed (Pkd1fl/fl) tamoxifen inducible cre mice were kindly provided by Gregory 6 
Germino.[52] Male and female Pkd1fl/fl cre+ and Pkd fl/fl cre- mice were used. We in-7 
duced recombinase activity at days 15, 17, and 19 by injecting pups with 100 µl ta-8 
moxifen (2.5mg/ml) in corn oil. All animal studies were performed according to proto-9 
cols approved by the legal authority (Veterinary Office of the Canton of Zurich). 10 
 11 
Plasma and urine analysis 12 
Blood and spot urine was collected from cy/+ and +/+ control rats at week 2, 4, 13 
6, and 8 after birth. Some rats included in the week 6 group were sacrificed between 14 
5 and 6 weeks after birth. Plasma and urine aliquots were rapidly frozen and stored 15 
at -80°C until measurement. Plasma concentrations of phosphate, calcium, and urea 16 
and urinary concentrations of phosphate and calcium were measured by the Institute 17 
of Clinical Chemistry at the University Hospital Zurich using standard methods. 18 
Pkd1fl/fl mice were fasted overnight before urine was collected for six hours in meta-19 
bolic cages (Tecniplast®, Italy). Afterwards the mice were anesthetized with isoflu-20 
rane and blood was collected from the heart. Urine and plasma laboratory analysis 21 
were performed by the Zurich Integrative Rodent Physiology (ZIRP) core facility. 22 
The ratio of the maximum rate of tubular phosphate reabsorption to the glome-23 
rular filtration rate (TmP/GFR) was calculated as follows: 24 
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TmP/GFR in mmol/L = PP - [UP x Pcrea / Ucrea] 1 
where PP, UP, Pcrea , and Ucrea refer to the plasma and urinary concentration of phos-2 
phate and creatinine, respectively.[53] The fractional excretion of calcium was calcu-3 
lated according to the following equation: 4 
FECa = (UCa x Pcrea)/(PCa x Ucrea) x 100 5 
where PCa, UCa, Pcrea, and Ucrea refer to the plasma and urinary concentrations of cal-6 
cium and creatinine, respectively. 7 
The plasma concentration of intact FGF23 (Kainos Laboratories, Tokyo, Ja-8 
pan), intact PTH (Immutopics International, California, USA) and 1,25(OH)2 vitamin 9 
D3 (Immunodiagnostic Systems, London, UK) were measured by enzyme-linked im-10 
munosorbent assays according to the manufacturer's protocols. 11 
RNA extraction and RT-PCR 12 
Rats were sacrificed at week 2, 4, and 8 for harvesting kidney, bone, liver, 13 
spleen, and heart. Mice were sacrificed at week 10 for harvesting kidneys and bone. 14 
The organs were rapidly frozen in liquid nitrogen. Total RNA was extracted using the 15 
Qiagen RNeasy Mini Kit (Qiagen, Hombrechtikon, Switzerland) or TRizol reagent for 16 
bone tissue (Invitrogen, Zug, Switzerland). Snap-frozen tissue slices were homoge-17 
nized in a pestle homogenizer (Potter-Elvehjem type) together with 1ml precooled 18 
RLT-Buffer supplemented with β-mercaptoethanol at a final concentration of 1%. 19 
Subsequently, 700 µl of the homogenate were used for RNA preparation, which was 20 
carried out according to the manufacturer's protocol. DNAse digestion was performed 21 
using the RNase-free DNAase Set (Qiagen; Hilden, Germany). Total RNA extractions 22 
were analyzed for quality, purity, and concentration using the NanoDrop ND-1000 23 
spectrophotometer (Wilmington, DE, USA). RNA samples were diluted to a final con-24 
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centration of 100 ng/µl and cDNA was prepared using the TaqMan Reverse Tran-1 
scriptase Reagent Kit (Applied Biosystems, Roche; Forster City, CA, USA). 2 
In brief, in a reaction volume of 40 µl, 300 ng of RNA was used as template 3 
and mixed with the following final concentrations of RT buffer (1x), MgCl2 (5.5 mM), 4 
random hexamers (2.5 µM), dNTP mix (500 µM each), RNase inhibitor (0.4 U/µl), 5 
multiscribe reverse transcriptase (1.25 U/µl) and RNAse-free water. Reverse tran-6 
scription was performed with thermocycling conditions set at 25°C for 10 min, 48°C 7 
for 30 min, and 95°C for 5 min on a thermocyler (Biometra, Goettingen, Germany). 8 
Quantitative real-time PCR (qRT-PCR) was performed on the ABI PRISM 9 
7700 Sequence Detection System (Applied Biosystems). Primers for all genes of in-10 
terest (Supplementary Table 1) were designed using Primer Express software from 11 
Applied Biosystems. Primers were chosen to result in amplicons no longer than 150 12 
bp spanning intron-exon boundaries to exclude genomic DNA contamination. The 13 
specificity of all primers was first tested on mRNA derived from kidney, bone or intes-14 
tine and always resulted in a single product of the expected size (data not shown). 15 
Probes were labelled with the reporter dye FAM at the 5'-end and the quencher dye 16 
TAMRA at the 3'-end (Microsynth, Balgach, Switzerland). Real-Time PCR reactions 17 
were performed using TaqMan Universal PCR Master Mix (Applied Biosystems) as 18 
described [10]. 19 
32P and 3H-glucose-uptake in brush border membrane vesicles 20 
Brush border membrane vesicles were prepared using the Mg2+-precipitation 21 
technique [54, 55] and further used for western blotting and transport studies. The 22 
transport rate of 32-labeled phosphate and tritium labeled glucose into renal brush 23 
border membrane vesicles was determined at 30s and 120min (equilibrium value) as 24 
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described [54] at 25°C in the presence of inward gradients of 100 mM NaCl or 100 mM 1 
KCl and 0.1 mM K2HPO4. All measurements were performed in triplicates. 2 
Western blot analysis  3 
After measurement of the protein concentration (Bio-Rad, Hercules, CA), 10 4 
µg of renal brush border membrane for NaPi-IIa and NaPi-IIc and 20 µg or 2 µg, re-5 
spectively, of total kidney homogenate for FRS2a/pFRS2a and Klotho was solubilized 6 
in loading buffer containing DTT and separated on 8% polyacrylamide gels. For im-7 
munoblotting, proteins were transferred electrophoretically to polyvinylidene fluoride 8 
membranes (Immobilon-P, Millipore, Bedford, MA, USA). After blocking with 5% milk 9 
powder in Tris-buffered saline/0.1% Tween-20 for 60min, blots were incubated with 10 
the primary antibodies: rabbit polyclonal anti-NaPi-IIa (1:6000),[56, 57] rabbit polyclonal 11 
anti-NaPi-IIc (1:10000),[10] mouse monoclonal anti-β-actin antibody (42kD; Sigma, St. 12 
Louis, MO; 1:5000), mouse monoclonal anti-FRS2a (R&D Systems, USA; 1:1500), 13 
rabbit polyclonal anti-pFRS2a (Cell Signaling Technology, USA; 1:2000), rat mono-14 
clonal anti-Klotho (Clone KM2076, TransGenic Inc., Japan; 1:1000) and mouse 15 
monoclonal anti-GAPDH (Merck Millipore, USA; 1:20000) either for 2h at room tem-16 
perature or overnight at 4°C. Membranes were then incubated for 1h at room tem-17 
perature with secondary goat anti-rabbit, donkey anti-mouse or goat anti-rat antibod-18 
ies (1:5000) linked to alkaline phosphatase (Promega, USA), HRP (Amersham, USA 19 
or R&D Systems, USA). The protein signal was detected with the appropriate sub-20 
strates using the DIANA III-chemiluminescence detection system (Raytest, 21 
Straubenhardt, Germany). All images were analyzed using the software Advanced 22 
Image Data Analyser AIDA, Raytest to calculate the protein of interest/actin ratio. 23 
 24 
 25 
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Immunofluorescence staining 1 
Rat kidneys were perfused in situ through the left heart ventricle with a fixative 2 
solution containing 3% paraformaldehyde in phosphate buffered saline (PBS). Mouse 3 
kidneys were immersed in a fixative solution containing formalin (10%). Kidneys were 4 
embedded in TissueTec and frozen in liquid nitrogen cooled by liquid propane. Five 5 
µm cryosections were cut. Slides were washed in PBS and incubated in 50 mM 6 
NH4Cl in PBS for 20 min at room temperature to reduce free aldehyde groups. For 7 
FGF23 staining, slides were treated for 5 min with 0.5% SDS in PBS. Unspecific sites 8 
were blocked with 1% bovine serum albumin (BSA) in PBS for 1h at room tempera-9 
ture. Primary antibodies were diluted in 1% BSA in PBS (NaPi-IIa 1:1000; anti-FGF23 10 
(R&D Systems, USA) 1:1000; anti-Calbindin (Swant, Switzerland) 1:20000) and kid-11 
ney sections were incubated with the primary antibody over night at 4°C. After wash-12 
ing with PBS, sections were incubated with the corresponding secondary antibody 13 
(1:500) (anti-rabbit Alexa594 (Invitrogen, Switzerland), anti-rat NL493 (R&D Systems, 14 
USA); anti-mouse (DyLight 649, Jackson ImmunoResearch, Europe), phalloidin-FITC 15 
(1:200), and DAPI (Invitrogen,1:1000) for 1h at room temperature. Slides were 16 
washed twice with PBS before being mounted with Dako glycergel mounting medium. 17 
Sections were visualised on a Leica DM 5500B fluorescence microscope and images 18 
processed with Adobe Photoshop CS5 extended. 19 
Statistical analysis 20 
Statistics were performed using unpaired Student’s t-test (GraphPad Prism 21 
version 5.0, GraphPad, San Diego, CA). Random-effects models for longitudinal data 22 
were applied to analyse unbalanced repeated measures (SAS version 9.3, Cary, NC, 23 
USA). Data are provided as mean ± SD. P < 0.05 was considered significant. 24 
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TITLES AND LEGENDS 1 
Figure 1 2 
FGF23, PTH and renal function. Plasma concentrations of FGF23 (a), PTH (b), 3 
creatinine (c) and urea (d) after 2, 4, 6, and 8 weeks in cy/+ (black squares) and +/+ 4 
(white squares) Han:SPRD rats (mean ±SD); number of animals (median), 5 
cy/+ = 11.5, +/+ = 11; * p<0.05 and ** p<0.001 6 
 7 
Figure 2 8 
FGF23 expression in kidney. (a) Relative mRNA expression of FGF23 to 18S rRNA 9 
in bone and kidney after 2, 4, and 8 weeks in cy/+ (black bars) and +/+ (white bars) 10 
Han:SPRD rats (mean ±SD); number of animals (median), cy/+ = 6, +/+ = 5.5; ** 11 
p<0.001. Immunohistochemistry for FGF23 (green), calbindin D28k (red), a marker 12 
for distal convoluted tubules and connecting tubules, and DAPI (blue, cell nuclei): 13 
(b,c) kidneys from 8 week old cy/+ rats, (d,e) kidneys from 8 week old control rats, (f) 14 
kidney from 8 week old cy/+ rat incubated with secondary antibodies alone. Original 15 
magnification 400 x. 16 
 17 
Figure 3 18 
Vitamin D3 metabolism. Plasma concentration of 1,25(OH)2 Vitamin D3 (a), relative 19 
mRNA expression of the vitamin D receptor (VDR) (b) as well as Cyp27b1 (c) and 20 
Cyp24a1 (d) enzymes in the kidney to 18S rRNA after 2, 4, and 8 weeks in cy/+ 21 
(black bars) and +/+ (white bars) Han:SPRD rats (mean ±SD); number of animals 22 
(median), cy/+ = 6, +/+ = 5; * p<0.05 and ** p<0.001. 23 
 24 
 25 
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Figure 4 1 
Renal phosphate and calcium handling. Plasma concentrations of phosphate (a) 2 
and calcium (b) as well as TmP/GFR (c) and FECa ratio (d) after 2, 4, 6, and 8 weeks 3 
in cy/+ (black squares) and +/+ (white squares) Han:SPRD rats (mean ±SD); number 4 
of animals (median), cy/+ = 11.5, +/+ =11; * p<0.05. 5 
 6 
Figure 5 7 
Phosphate transporter mRNA expression. Relative mRNA expression of NaPi-IIa 8 
(a) and NaPi-IIc (b) to 18S rRNA after 2, 4, and 8 weeks in cy/+ (black bars) and +/+ 9 
(white bars) Han:SPRD rats (mean ±SD); number of animals (median), cy/+ = 6, 10 
+/+ = 6; * p<0.05. 11 
 12 
Figure 6 13 
Phosphate transporter protein expression. Relative protein expression of NaPi-IIa 14 
and NaPi-IIc to β-actin after 2 (a), 4 (b), and 8 (c) weeks in cy/+ (black bars) and +/+ 15 
(white bars) Han:SPRD rats (mean ±SD); number of animals (median), cy/+ = 6, 16 
+/+ = 6; * p<0.05. 17 
 18 
Figure 7 19 
Phosphate and glucose uptake into renal brush border membrane vesicles. 20 
Phosphate uptake without (a) and with (b) PFA and glucose uptake (c) after 2, 4, and 21 
8 weeks in cy/+ (black bars) and +/+ (white bars) Han:SPRD rats (mean ±SD); num-22 
ber of animals (median), cy/+ = 11, +/+ = 7; * p<0.05. 23 
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Figure 8 1 
Klotho expression and phosphorylation state of FRS2a. Relative mRNA expres-2 
sion of Klotho in kidney (a) to 18S rRNA after 2, 4, and 8 weeks; relative protein ex-3 
pression of Klotho (b) and phosphorylation state of FRS2a (c) to GAPDH after 8 4 
weeks in cy/+ (black bars) and +/+ (white bars) Han:SPRD rats (mean ±SD); number 5 
of animals (median), cy/+ = 4, +/+ = 4; * p<0.05. 6 
 7 
Figure 9 8 
FGF23, PTH, TmP/GFR, and renal function in Pkd1fl/fl mice. Plasma intact FGF23 9 
(a) and PTH (b) as well as TmP/GFR (c) and creatinine clearance (d) after 10 weeks 10 
in Pkd1fl/fl, cre+ (black bars) and Pkd1fl/fl, cre- (white bars) mice (mean ±SD); number 11 
of animals (median), Pkd1fl/fl, cre+ = 7, Pkd1fl/fl, cre- = 16; * p<0.05. 12 
 13 
Figure 10 14 
FGF23 and Klotho expression in bone and kidneys of Pkd1fl/fl mice. 15 
Relative mRNA expression of FGF23 in kidney (a) and bone (b) as well as Klotho in 16 
kidney (c) to 18S rRNA after 10 weeks in Pkd1fl/fl, cre+ (black bars) and Pkd1fl/fl, cre- 17 
(white bars) mice (mean ±SD), Pkd1fl/fl, cre+ = 8, Pkd1fl/fl, cre- = 15 * p<0.05 and ** 18 
p<0.001. 19 
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Supplementary Figures 
 
Suppl. Figure 1 
Renal function after fasting overnight of 4 weeks old HanSPRD rats. Plasma 
phosphate (a), plasma total calcium (b), TmP/GFR (c), and creatinine clearance after 
4 weeks in cy/+ (black bars) and +/+ (white bars) HanSPRD rats; number of animals 
(median), cy/+ n = 12, +/+ n = 8 
 
Suppl. Figure 2 
mRNA expression of FGF23 regulatory molecules in kidney and bone. Relative 
mRNA expression of Fam20c and Dmp1 in kidney (a, c) and bone (b, d) after 4 and 8 
weeks in cy/+ (black bars) and +/+ (white bars) Han:SPRD rats; number of animals 
(median), cy/+ n = 7, +/+ n = 5; * p<0.05 
 
Suppl. Figure 3 
Immunolocalization of NaPi-IIa. Frozen kidney sections were stained with 
antibodies against NaPi-IIa (red), Phalloidin-FITC for actin (green), and DAPI (blue) 
in cy/+ and +/+ animals after 4 and 8 weeks. Scale bar 50 µm.  
 
Suppl. Figure 4 
Heart wall thickness and heart weight. Heart wall (a) and septum thickness (c) of 4 
weeks old HanSPRD rats; heart weight of 10 weeks old rats normalized to body 
weight (b) and tibia length (d); number of animals (median), cy/+ = 5, +/+ = 4  
 
Suppl. Figure 5 
FGFR-1 mRNA expression. Relative mRNA expression of the FGF receptor 1 
(FGFR-1) in bone (a) and kidney (b) to 18S rRNA after 2, 4, and 8 weeks in cy/+ 
(black bars) and +/+ (white bars) Han:SPRD rats (mean ±SD); number of animals 
(median), cy/+ n = 6, +/+ n = 5  
 
Suppl. Figure 6 
Pkd1 mRNA expression. Relative Pkd1 mRNA abundance in kidney (a) and bone 
(b) of 10 weeks old Pkd1fl/fl, cre+ (black bars) compared to Pkd1fl/fl, cre- (white bars) 
mice (mean ±SD); number of animals (median), Pkd1fl/fl, cre+ n = 8, Pkd1fl/fl, cre- n 
= 15; ** p<0.001 
 
Suppl. Figure 7 
Expression of FGF23 in kidneys from Pkdfl/fl, cre+ KO mice. Frozen kidney 
sections were stained for FGF23 (green), calbindin D28k, a marker of DCT and CNT 
segments (red), and DAPI (cell nuclei). In kidneys from Pkd1fl/fl, cre+ mice strong 
FGF23 staining is observed in cells lining the cysts (a,b), no staining for FGF23 is 
observed in kidneys from Pkd1fl/fl, cre- mice (c,d). Omission of primary antibodies in P 
Pkd1fl/fl, cre+ kidneys showed no staining (e). Original magnification 400 x. 
 
Supplementary Table 1 
Primer and probe sequences used for RT-PCR 
Gene Primers Probe 
Rat NaPi-IIa 
(Slc34a1) 
F: 5'-GGAATCACAGTDTCATTCGGATT-3' 5'-TGTCAACCAGAGACAAAAGA 
GGCTTCCACT-3' R: 5'-ATGGCCTCTACCCTGGACATAG-3' 
Rat NaPi-IIc 
(Slc34a3) 
F: 5'-GGGATCGGGATGAATTTCAGA-3'  5'-ACGGCATCTTCAACTGGCTC 
ACAGTGTT-3' R: 5'-GGGCCAGCTCACTCAGTCTCT-3' 
Rat FGF23 
F: 5'-GCAACATTTTTGGATCGTATCA-3' 5'-AGATTCCGCCAGTGGACGCT 
AGAGA-3' R: 5'-GATGCTTCGGTGACAGGTAGA-3' 
Rat Klotho 
F: 5'-TATCTCAAGAAGTTCATAATGGAAAGC-3' 5'-TAAAAGCCATCAGGCTGGAT 
GGGG-3' R: 5'-GAGGGACCATGCGGTGTA-3' 
Rat FGFR1 
F: 5'-GGTTGAAAAATGGCAAGGAA-3' 5'-TCGGAGGCTACAAGGTTCGT 
TACGC-3' R: 5'-CCACGATGCAGGTGTAGTTG-3' 
Rat Cyp24a1 
F: 5'-CAAATCAGTCAAACCCTGCAT-3' 5'-TACAGAGATATTCCCAGCAG 
CCCGG-3' R: 5'-GGCGTACAGTTCCTTCTTGG-3' 
Rat Cyp27b1 
F: 5'-TGGCAAACGAAGTTGCATAG-3' 5'-CTACAAATGGCGTTGGCCCA 
GATC-3' R: 5'-AGCACCTCAAAATGGGTCAA-3' 
Rat Fam20c 
F: 5'-CCATCGATGCCTTACTCCAC-3' 5'-CAGAAGATCACCAGTGTCGC 
CATGA-3' R: 5'-CCCGTAATTCTGGAAGGTCA-3' 
Rat Dmp1 F: 5'-CTGTCCTGTGCTCTCCCTGT-3' 5'-TCTGAAAGCTCCGAAGAGAG 
R: 5'-GCTGTCCGTGTGGTCACTATT-3' GACGG-3' 
Mouse Pkd1 
F: 5'-GGCCAACCTCTCCTCAGTATC-3' 5’-CTGTGGTGAGGAATATGTCG 
CCTGC-3’ R: 5'-GAAGGGTACTGCTGCCACA-3' 
Mouse FGF23 
F: 5'-TCGAAGGTTCCTTTGTATGGAT-3' 5'-TTTTTGGATCGCTTCACT-3' 
  R: 5'-AGTGATGCTTCTGCGACAAGT-3' 
Mouse Klotho 
F: 5'-ACGTTCAAGTGGACACTACTCTCTC-3' 5'-CCGAATGTCTATCTGTGGGA 
TGTGCA-3' R: 5'-TTGGCTACAACCCCGTCTAC-3' 
 
Supplementary Methods 
H&E histology 
Hearts were fixed in 10% buffered formalin over night and embedded in paraffin. 
Sections were stained with Hematoxilin-Eosin following routine protocols. 
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